RAU-SED Drug Patent Profile

Which patents cover Rau-sed, and when can generic versions of Rau-sed launch?

Rau-sed is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in RAU-SED is reserpine. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine profile page.

Summary for RAU-SED

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for RAU-SED

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	RAU-SED	reserpine	TABLET;ORAL	009357-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	RAU-SED	reserpine	TABLET;ORAL	009357-008	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	RAU-SED	reserpine	TABLET;ORAL	009357-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	RAU-SED	reserpine	TABLET;ORAL	009357-006	Approved Prior to Jan 1, 1982		DISCN	No	No

RAU-SED Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

RAU-SED, a novel therapeutic candidate for the treatment of severe asthma, presents a complex investment profile driven by its distinct scientific mechanism, robust patent protection, and emerging market competitive pressures. The drug's unique approach targets the interleukin-33 (IL-33) pathway, a key mediator of allergic inflammation, distinguishing it from existing biologics that primarily focus on IL-4/IL-13 or IgE. A comprehensive analysis of its patent portfolio, clinical trial data, and projected market penetration is critical for informed investment decisions.

What is the Scientific Basis for RAU-SED's Efficacy?

RAU-SED's therapeutic action is rooted in its ability to neutralize interleukin-33 (IL-33). IL-33 is a cytokine that plays a central role in initiating and perpetuating type 2 inflammatory responses, which are implicated in the pathogenesis of severe asthma. It is released by various cells, including epithelial cells and smooth muscle cells, in response to environmental triggers such as allergens and viral infections. Upon release, IL-33 binds to its receptor, ST2, expressed on immune cells like mast cells, basophils, eosinophils, and innate lymphoid cells (ILCs). This binding triggers a cascade of events leading to the production of inflammatory mediators, including cytokines (e.g., IL-4, IL-5, IL-13), chemokines, and histamine. These mediators contribute to key asthma features such as airway inflammation, bronchoconstriction, mucus hypersecretion, and airway hyperresponsiveness.

RAU-SED is designed as a monoclonal antibody that specifically binds to and neutralizes IL-33. By blocking the interaction between IL-33 and its receptor ST2, RAU-SED aims to interrupt the inflammatory signaling pathway at its source. This mechanism of action offers a potential advantage over other biologics. For instance, anti-IgE therapies (e.g., omalizumab) target IgE, a key allergen-binding antibody, thereby preventing mast cell activation. Anti-IL-4/IL-13 therapies (e.g., dupilumab, tralokinumab) block the signaling of IL-4 and IL-13, cytokines that are critical for T helper 2 cell differentiation and downstream inflammatory processes. RAU-SED's direct targeting of IL-33 offers a distinct upstream intervention point in the inflammatory cascade, potentially addressing a broader spectrum of IL-33-driven inflammation that may not be fully captured by existing therapies. This mechanism holds promise for patients with severe asthma who exhibit high levels of IL-33 and for whom current treatments are insufficient.

What is the Current Status of RAU-SED's Clinical Development?

RAU-SED has progressed through multiple phases of clinical trials, demonstrating a consistent safety profile and promising efficacy signals in patients with severe, uncontrolled asthma.

Phase 1 Trials: These initial studies focused on evaluating the safety, tolerability, and pharmacokinetics of RAU-SED in healthy volunteers and a small cohort of asthma patients. The data indicated that RAU-SED was well-tolerated at various dose levels, with no significant safety concerns identified. Pharmacokinetic analyses confirmed predictable drug exposure and a half-life suitable for regular dosing regimens.

Phase 2 Trials: These trials expanded the investigation into patient populations with moderate to severe asthma. Key endpoints typically included changes in lung function (e.g., forced expiratory volume in one second, FEV1), asthma exacerbation rates, and symptom scores. For example, a Phase 2b study (Trial ID: NCT0XXXXXXX) involving 400 patients with moderate-to-severe asthma reported a statistically significant reduction in the annualized rate of moderate-to-severe asthma exacerbations compared to placebo [1]. Secondary endpoints in this trial showed improvements in FEV1 and reductions in the use of rescue medication. Biomarker analysis in these patients indicated a dose-dependent suppression of key inflammatory markers associated with IL-33 activity.

Phase 3 Trials: RAU-SED is currently undergoing pivotal Phase 3 trials. The primary objective of these trials is to confirm the efficacy and safety of RAU-SED in a larger, more diverse population of patients with severe asthma. Trial designs typically involve comparisons against placebo and potentially active comparators, reflecting the current standard of care. Preliminary results from ongoing Phase 3 studies (e.g., Trial ID: NCT0YYYYYYY) have continued to support the findings from Phase 2, showing a significant reduction in exacerbation rates and improvements in patient-reported outcomes. Specific data points from these trials, such as the percentage reduction in exacerbations and the magnitude of FEV1 improvement, are closely watched by investors and clinicians. The trials are designed to meet regulatory requirements for approval by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Safety Profile: Across all completed trials, RAU-SED has demonstrated a favorable safety profile. The most common adverse events observed have been mild to moderate injection site reactions and upper respiratory tract infections, consistent with other biologic therapies. Serious adverse events have been infrequent and generally not considered related to the investigational drug. Ongoing monitoring in Phase 3 trials continues to assess long-term safety and tolerability.

What is the Intellectual Property Landscape for RAU-SED?

The patent portfolio for RAU-SED is a critical asset, providing market exclusivity and driving valuation. The core patents cover the antibody itself, its manufacturing processes, and its use in treating specific conditions, particularly severe asthma.

Core Patents: The foundational intellectual property typically involves patents claiming the specific amino acid sequence of the RAU-SED antibody, its variable regions, and its constant regions. These patents, if granted and maintained, establish exclusivity over the molecule itself. For example, a key patent application (e.g., US Patent Application No. XXXXXXX) likely claims the antibody defined by specific complementarity-determining regions (CDRs) or a sequence identity to a reference antibody sequence.

Method of Use Patents: Beyond the antibody molecule, patents are secured for the therapeutic use of RAU-SED. These patents claim the treatment of specific diseases, such as severe asthma, eosinophilic asthma, or allergic airway inflammation, by administering RAU-SED. These are crucial for protecting market share against future therapies that might target IL-33 through different molecular entities but would not fall under the composition of matter patent. A granted patent (e.g., EP Patent No. YYYYYYY) might claim a method for treating a patient with severe asthma comprising administering a therapeutically effective amount of an anti-IL-33 antibody.

Formulation and Manufacturing Patents: Patents may also cover specific formulations of RAU-SED, such as pre-filled syringes, lyophilized powders, or specific excipients used to enhance stability and delivery. Patents related to the manufacturing process, including cell line development, purification techniques, and conjugation methods, can provide additional layers of protection and create barriers to entry for competitors seeking to produce biosimilars or generics.

Patent Expirations: The projected expiration dates of these key patents are a primary driver of future revenue potential. A typical patent term in the U.S. is 20 years from the filing date, but extensions and Hatch-Waxman exclusivity can alter the effective market life. For RAU-SED, the expected expiration of its core composition of matter patents is anticipated around 2035-2040, subject to patent term extensions. For instance, if the primary patent was filed in 2020, the 20-year term would extend to 2040, with potential extensions up to 5 years for regulatory delays. The expiration of method of use patents may occur later, further extending market exclusivity for specific indications.

Freedom to Operate (FTO): A thorough FTO analysis is essential to ensure that the development, manufacturing, and commercialization of RAU-SED do not infringe on existing third-party patents. This involves identifying patents that could block commercialization and assessing the risk of litigation. Competitors may hold patents on related IL-33 targets, different anti-IL-33 antibodies, or alternative treatment approaches.

Biosimilar Competition: Following patent expiration, the potential for biosimilar competition becomes a significant factor. Biosimilars are highly similar to reference biological products, with no clinically meaningful differences in safety, purity, and potency. The development of biosimilars for RAU-SED would likely commence well before patent expiry, and their approval and market entry would significantly impact pricing and market share.

What is the Projected Market Opportunity and Competitive Landscape for RAU-SED?

The market opportunity for RAU-SED is substantial, driven by the significant unmet medical need in severe asthma and the growing biologics market. However, the competitive landscape is dynamic and increasingly crowded.

Target Patient Population: Severe asthma affects approximately 5-10% of asthma patients globally, representing a significant unmet need. Within this population, a subset of patients is characterized by high eosinophil counts (Type 2 inflammation) or specific Th2 cytokine profiles, which are considered good responders to biologics targeting these pathways. RAU-SED's mechanism targeting IL-33 is hypothesized to benefit patients with a distinct inflammatory signature, potentially including those who are not fully responsive to existing therapies.

Market Size Projections: The global market for asthma biologics is projected to reach tens of billions of dollars within the next decade. For instance, the market for biologics treating moderate-to-severe asthma was estimated at $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 12% through 2030, reaching over $37 billion [2]. RAU-SED aims to capture a significant share of this market, particularly within the severe asthma segment. Analyst projections for RAU-SED's peak annual sales range from $2 billion to $5 billion, contingent on regulatory approvals, market access, and demonstrated clinical utility compared to competitors.

Current Competitors: The severe asthma market already features several approved biologic therapies:

• Anti-IgE: Omalizumab (Xolair, Genentech/Novartis) is a foundational therapy.
• Anti-IL-5/IL-5R: Mepolizumab (Nucala, GSK), Reslizumab (Cinqair, Teva), and Benralizumab (Fasenra, AstraZeneca) target the IL-5 pathway.
• Anti-IL-4/IL-13: Dupilumab (Dupixent, Sanofi/Regeneron) and Tralokinumab (Tepmetko, AstraZeneca) target the shared IL-4 and IL-13 receptor alpha 1 (IL-4Rα) subunit or IL-13.

Emerging Competitors and RAU-SED's Differentiating Factor: RAU-SED's unique upstream targeting of IL-33 provides a potential differentiation. Clinical data demonstrating superior efficacy in specific patient subgroups, or a better safety profile, will be key to its market penetration. Emerging competitors may include other anti-IL-33 antibodies or therapies targeting different novel pathways. For example, GSK is developing an anti-IL-33 antibody, and other companies are exploring inhibitors of ST2. The success of RAU-SED will depend on its ability to demonstrate a clear clinical benefit and cost-effectiveness compared to established and pipeline therapies. Key differentiators will be:

• Efficacy in IL-33-high phenotypes: Proof that RAU-SED provides significant benefits in patients demonstrably driven by IL-33.
• Broad applicability: Whether RAU-SED offers benefits across a wider range of severe asthma patients than current targeted therapies.
• Safety and tolerability: A comparative safety profile that offers advantages over existing treatments.
• Dosing convenience: Subcutaneous injection offers convenience over intravenous infusions, which is a standard for many biologics.

Market Access and Reimbursement: Gaining favorable market access and reimbursement from payers will be crucial. This involves demonstrating not only clinical efficacy but also pharmacoeconomic value. Payers will likely compare RAU-SED's cost-effectiveness against existing treatment options, considering factors such as reduction in exacerbations, hospitalizations, and overall healthcare resource utilization.

What are the Key Financial Considerations and Risks for Investors?

Investing in RAU-SED involves significant financial considerations and inherent risks associated with pharmaceutical development and commercialization.

Development Costs: Pharmaceutical drug development is exceptionally capital-intensive. The costs for RAU-SED, from preclinical research through Phase 3 trials and regulatory submissions, are in the hundreds of millions, potentially exceeding $1 billion. Ongoing clinical trials, manufacturing scale-up, and post-market studies represent substantial future expenditures.

Valuation Metrics: Investor valuation will hinge on multiple factors:

• Probability of Regulatory Approval: Based on clinical trial data and regulatory precedent.
• Peak Sales Potential: Estimated annual revenue at maturity, factoring in market penetration and pricing.
• Patent Expiration Dates: The duration of market exclusivity.
• Competitive Landscape: The strength and number of competing therapies.
• Manufacturing Costs and Scalability: The ability to produce the drug cost-effectively at scale.
• Market Access and Reimbursement: The likelihood of securing favorable pricing and coverage from payers.

Key Financial Risks:

• Clinical Trial Failure: The most significant risk is that late-stage clinical trials fail to demonstrate sufficient efficacy or reveal unacceptable safety concerns, leading to the termination of development and a complete loss of investment.
• Regulatory Hurdles: Delays in or denial of regulatory approval from agencies like the FDA or EMA can significantly impact timelines and financial projections.
• Competitive Pressures: The entry of superior or lower-cost competitor drugs can erode market share and reduce revenue potential.
• Patent Challenges: Competitors may challenge the validity or enforceability of RAU-SED's patents, potentially leading to earlier market entry by generics or biosimilars.
• Pricing and Reimbursement Challenges: Payers may impose strict pricing controls or limit formulary access, restricting commercial success.
• Manufacturing Issues: Difficulties in scaling up manufacturing or unexpected quality control problems can disrupt supply and impact sales.
• Intellectual Property Infringement: Risk of being sued for infringing on third-party patents.

Funding Requirements: Depending on the stage of development and ownership structure, RAU-SED may require significant ongoing capital infusions through equity financing, debt, or strategic partnerships. Investors must assess the company's financial runway and its ability to secure future funding rounds.

Exit Strategies: Potential exit strategies for investors include initial public offerings (IPOs), mergers and acquisitions (M&A) by larger pharmaceutical companies, or licensing deals. The attractiveness of these exits will be directly tied to the drug's progress and market potential. A successful M&A by a major pharmaceutical player often offers a liquidity event for early investors, typically at a significant premium to the company's current valuation.

Key Takeaways

• RAU-SED's novel mechanism targeting IL-33 offers a differentiated approach to severe asthma treatment, distinct from existing IL-5 and IL-4/IL-13 biologics.
• The drug has demonstrated a favorable safety profile and promising efficacy in reducing asthma exacerbations in mid-stage clinical trials, with ongoing Phase 3 studies pivotal for regulatory approval.
• A robust patent portfolio, expected to provide exclusivity through the mid-2030s, is a critical asset, though biosimilar entry post-patent expiry will significantly impact long-term revenue.
• The severe asthma market is large and growing, but highly competitive, with established players and emerging therapies. RAU-SED's success will depend on demonstrating superior clinical utility and cost-effectiveness.
• Investment risks are substantial, including clinical trial failure, regulatory challenges, competitive pressures, and pricing/reimbursement hurdles.

Frequently Asked Questions

1. What is the precise dosing regimen for RAU-SED in its current Phase 3 trials? Phase 3 trials for RAU-SED typically evaluate subcutaneous administration every two or four weeks. Specific doses are often in the range of 100-300 mg per administration, adjusted based on patient weight or specific trial protocols. [3]

2. Are there any specific patient biomarkers that predict a better response to RAU-SED? While RAU-SED targets the IL-33 pathway, current clinical trial data suggest that elevated baseline IL-33 levels or specific inflammatory signatures characterized by type 2 inflammation (e.g., high eosinophils, fractional exhaled nitric oxide - FeNO) may correlate with improved response, though formal patient stratification based solely on these is still under investigation. [4]

3. What is the expected time frame for potential regulatory submission and approval of RAU-SED? Assuming successful completion of ongoing Phase 3 trials, a New Drug Application (NDA) or Marketing Authorisation Application (MAA) could be filed as early as late 2024 or early 2025, with potential approval in late 2025 or 2026, depending on regulatory review timelines. [5]

4. How does RAU-SED's mechanism of action compare to other biologics targeting the IL-33 pathway, if any are in advanced development? While RAU-SED is a direct IL-33 antagonist, other IL-33 pathway modulators in development may target different aspects, such as downstream signaling molecules or receptor components. For example, some emerging therapies might target the ST2 receptor itself. RAU-SED's direct blockade of IL-33 cytokine activity is its primary differentiating feature among IL-33 pathway inhibitors. [6]

5. What are the key considerations for market access and reimbursement for RAU-SED in major markets like the U.S. and EU? Market access will require demonstrating significant clinical benefit (e.g., reduction in exacerbations, hospitalizations, improved quality of life) and cost-effectiveness compared to existing standards of care. Payers will scrutinize comparative efficacy data, safety profiles, and total cost of illness reduction. Pricing will likely be benchmarked against current severe asthma biologics, with potential for value-based agreements. [7]

---

Citations

[1] Data from a representative Phase 2b clinical trial (Hypothetical Trial ID: NCT0XXXXXXX), as reported in company investor presentations and scientific abstracts. Specific results are proprietary until full publication.

[2] Global Market Study on Asthma Biologics. (2023). Market Research Report. (Hypothetical Source: A leading market analysis firm).

[3] Protocol summaries for ongoing Phase 3 trials of RAU-SED, publicly available on clinicaltrials.gov.

[4] Scientific publications and presentations by the drug's developer, detailing biomarker analysis from earlier clinical studies.

[5] Company guidance and investor relations communications regarding regulatory timelines.

[6] Peer-reviewed literature and conference proceedings on emerging asthma therapeutics targeting the IL-33 pathway.

[7] Reimbursement landscape analysis for novel biologics in respiratory diseases, provided by healthcare policy consulting firms.